
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2176328/publications.pdf Version: 2024-02-01



RENIAMIN CADLIN

#	Article	IF	CITATIONS
1	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2022, 399, 665-676.	6.3	280
2	Severity of COVID-19 after Vaccination among Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 843-850.	2.2	34
3	Outcome and effect of vaccination in SARS-CoV-2 Omicron infection in hemodialysis patients: a cohort study. Nephrology Dialysis Transplantation, 2022, 37, 1944-1950.	0.4	14
4	"Epigenome-wide methylation profile of chronic kidney disease-derived arterial DNA uncovers novel pathways in disease-associated cardiovascular pathology.― Epigenetics, 2021, 16, 718-728.	1.3	10
5	Feasibility of evaluation of the natural history of kidney disease in the general population using electronic healthcare records. CKJ: Clinical Kidney Journal, 2021, 14, 1603-1609.	1.4	1
6	CKD and CKDu in northern Peru: a cross-sectional analysis under the DEGREE protocol. BMC Nephrology, 2021, 22, 37.	0.8	2
7	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2021, 397, 605-612.	6.3	234
8	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2021, 397, 1637-1645.	6.3	1,374
9	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet, The, 2021, 397, 2049-2059.	6.3	391
10	Risk of COVID-19 Disease, Dialysis Unit Attributes, and Infection Control Strategy among London In-Center Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1237-1246.	2.2	30
11	Identifying prognostic risk factors for poor outcome following COVID-19 disease among in-centre haemodialysis patients: role of inflammation and frailty. Journal of Nephrology, 2021, 34, 315-323.	0.9	21
12	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respiratory Medicine,the, 2021, 9, 1419-1426.	5.2	123
13	Lupus Nephritis and Chronic Kidney Disease. Journal of Rheumatology, 2020, 47, 1303-1304.	1.0	8
14	Prevalence and risk factors for chronic kidney disease of unknown cause in Malawi: a cross-sectional analysis in a rural and urban population. BMC Nephrology, 2020, 21, 387.	0.8	8
15	HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol. BMJ Open, 2020, 10, e033923.	0.8	1
16	FP377FEASIBILITY OF EVALUATION OF THE NATURAL HISTORY OF KIDNEY DISEASE USING PRIMARY CARE ELECTRONIC HEALTHCARE RECORDS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
17	Identification of young adults at risk of an accelerated loss of kidney function in an area affected by Mesoamerican nephropathy. BMC Nephrology, 2019, 20, 21.	0.8	8
18	Prevalence and risk factors for impaired kidney function in the district of Anuradhapura, Sri Lanka: a cross-sectional population-representative survey in those at risk of chronic kidney disease of unknown aetiology. BMC Public Health, 2019, 19, 763.	1.2	31

#	Article	IF	CITATIONS
19	CKD of Unknown Cause: AÂGlobal Epidemic?. Kidney International Reports, 2019, 4, 367-369.	0.4	18
20	Prevalence of and risk factors for chronic kidney disease of unknown aetiology in India: secondary data analysis of three population-based cross-sectional studies. BMJ Open, 2019, 9, e023353.	0.8	27
21	Let's take the heat out of the CKDu debate: more evidence is needed. Occupational and Environmental Medicine, 2019, 76, 357-359.	1.3	33
22	Chronic kidney disease of undetermined aetiology: tens of thousands of premature deaths, yet too much remains unknown. Nephrology Dialysis Transplantation, 2019, 34, 1839-1841.	0.4	5
23	Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE). BMJ Open, 2019, 9, e031169.	0.8	20
24	Epidemiology, molecular, and genetic methodologies to evaluate causes ofÂCKDuÂaroundÂthe world: report of the Working GroupÂfrom the ISN InternationalÂConsortium ofÂCollaborators onÂCKDu. Kidney International, 2019, 96, 1254-1260.	2.6	16
25	Environmental exposures in young adults with declining kidney function in a population at risk of Mesoamerican nephropathy. Occupational and Environmental Medicine, 2019, 76, 920-926.	1.3	27
26	The International Society of Nephrology's International Consortium ofÂCollaborators on Chronic Kidney Disease ofÂUnknown Etiology: report of the working groupÂon approaches to population-level detection strategies and recommendations forÂaÂminimumÂdataset. Kidney International, 2019, 95, 4-10.	2.6	45
27	The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2019, 30, 606.	0.4	9
28	Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe. Kidney International, 2018, 93, 1432-1441.	2.6	36
29	FP366OUTCOMES OF PEOPLE WITH CHRONIC KIDNEY DISEASE STAGES 3-5 MANAGED IN PRIMARY CARE IN THE UK - FINDINGS FROM THE NATIONAL CKD AUDIT. Nephrology Dialysis Transplantation, 2018, 33, i155-i155.	0.4	Ο
30	The National CKD Audit: a primary care condition that deserves more attention. British Journal of General Practice, 2018, 68, 356-357.	0.7	5
31	Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data. British Journal of General Practice, 2018, 68, e512-e523.	0.7	21
32	How do primary care doctors in England and Wales code and manage people with chronic kidney disease? Results from the National Chronic Kidney Disease Audit. Nephrology Dialysis Transplantation, 2018, 33, 1373-1379.	0.4	34
33	What do epidemiological studies tell us about chronic kidney disease of undetermined cause in Meso-America? A systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2018, 11, 496-506.	1.4	73
34	Decline in Kidney Function among Apparently Healthy Young Adults at Risk of Mesoamerican Nephropathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 2200-2212.	3.0	60
35	Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1. Journal of the American Society of Nephrology: JASN, 2017, 28, 2158-2166.	3.0	93
36	Rationale, description and baseline findings of a community-based prospective cohort study of kidney function amongst the young rural population of Northwest Nicaragua. BMC Nephrology, 2017, 18, 16.	0.8	18

#	Article	IF	CITATIONS
37	Accounting for overdispersion when determining primary care outliers for the identification of chronic kidney disease: learning from the National Chronic Kidney Disease Audit. Nephrology Dialysis Transplantation, 2017, 32, ii151-ii158.	0.4	5
38	Urinary biomarkers of tubular injury in chronic kidney disease. Kidney International, 2017, 91, 21-23.	2.6	11
39	International Collaboration for the Epidemiology of eGFR in Low and Middle Income Populations - Rationale and core protocol for the Disadvantaged Populations eGFR Epidemiology Study (DEGREE). BMC Nephrology, 2017, 18, 1.	0.8	145
40	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 185-193.	2.9	45
41	Chronic kidney disease-associated cardiovascular disease: scope and limitations of animal models. Cardiovascular Endocrinology, 2017, 6, 120-127.	0.8	5
42	MP313IDENTIFYING OUTLYING PRACTICES IN PREVALENCE OF CKD IN PRIMARY CARE. Nephrology Dialysis Transplantation, 2016, 31, i443-i443.	0.4	0
43	Infection Rates Following Buttonhole Cannulation in Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2016, 20, 476-482.	0.4	22
44	CME Renal medicine (100621): self-assessment questionnaire. Clinical Medicine, 2015, 15, 589-590.	0.8	0
45	SP847THE USE OF mTORi IN PATIENTS WITH RECURRENT CMV INFECTION AFTER KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2015, 30, iii656-iii657.	0.4	0
46	Peritoneal Protein Clearance Rather than Faster Transport Status Determines Outcomes in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2015, 35, 216-221.	1.1	39
47	Dimethylarginine Dimethylaminohydrolase 2 Regulates Nitric Oxide Synthesis and Hemodynamics and Determines Outcome in Polymicrobial Sepsis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1382-1392.	1.1	47
48	Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage. Journal of the American Society of Nephrology: JASN, 2015, 26, 3045-3059.	3.0	31
49	Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrology Dialysis Transplantation, 2015, 30, 1185-1192.	0.4	94
50	Does Online Haemodiafiltration Reduce Intra-Dialytic Patient Symptoms?. Nephron Clinical Practice, 2014, 124, 184-190.	2.3	19
51	Assessment of the Renal Patient. , 2014, , 1-17.		0
52	Chronic Kidney Disease: Cardiovascular Complications. , 2014, , 589-601.		0
53	Early changes in scores of chronic damage on transplant kidney protocol biopsies reflect donor characteristics, but not future graft function. Clinical Transplantation, 2013, 27, E669-78.	0.8	5
54	New Observational Data Demonstrate that Mortality Is Lower in Patients Receiving More Frequent Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 770-773.	3.0	3

#	Article	lF	CITATIONS
55	Endogenous Nitric Oxide Synthase Inhibitors in the Biology of Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1343-1353.	1.1	82
56	Alanine-Glyoxylate Aminotransferase-2 Metabolizes Endogenous Methylarginines, Regulates NO, and Controls Blood Pressure. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2892-2900.	1.1	70
57	Patients' perspective of haemodialysis-associated symptoms. Nephrology Dialysis Transplantation, 2011, 26, 2656-2663.	0.4	163
58	RENAL DISEASE IS ASSOCIATED WITH ACCELERATED VASCULAR AGEING: INITIAL RESULTS OF THE UK RESEARCH ALLIANCE INTO KIDNEY DISEASE AND ARTERIAL STIFFNESS (UREKA) COLLABORATION: 8A.02. Journal of Hypertension, 2010, 28, e417.	0.3	3
59	Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. Kidney International, 2010, 77, 459-467.	2.6	26
60	P9.09 DIFFERENCE IN AGE-RELATED PATTERNS OF ARTERIAL STIFFNESS AND WAVE REFLECTIONS AMONG PATIENTS WITH KIDNEY DISEASE: RESULTS OF THE UK RESEARCH ALLIANCE INTO KIDNEY DISEASE AND ARTERIAL STIFFNESS (UREKA) COLLABORATION. Artery Research, 2010, 4, 174.	0.3	1
61	Prospective Monitoring of Epstein-Barr Virus DNA in Adult Renal Transplant Recipients During the Early Posttransplant Period: Role of Mycophenolate Mofetil. Transplantation, 2009, 87, 852-856.	0.5	24
62	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Arterial Calcification in Dialysis Patients and Transplant Recipients. Seminars in Dialysis, 2007, 20, 144-149.	0.7	15
63	Antiviral treatment after solid organ transplantation. Lancet, The, 2005, 366, 806-807.	6.3	7
64	Dinucleotide repeat polymorphism at the HOX 2B locus. Human Molecular Genetics, 1992, 1, 218-218.	1.4	5